SOX13: A Non-Coding RNA Molecule as A Drug Target and Biomarker

Target Name: SOX13

NCBI ID: G9580

SOX13

SOX13: A Non-Coding RNA Molecule as A Drug Target and Biomarker

SOX13 (SRY-box transcription factor 13) is a non-coding RNA molecule that plays a crucial role in various cellular processes. It is a key regulator of gene expression and has been implicated in the development and progression of many diseases, including cancer. In this article, we will discuss SOX13 as a drug target and its potential as a biomarker for several diseases.

SOX13 is a member of the SOX gene family, which includes several transcription factors that are involved in the regulation of gene expression. SOX13 is characterized by a critical box that contains a domain similar to that of the transcription factor p53. This domain is responsible for the recruitment of SOX13 to target genes and for the regulation of their gene expression.

SOX13 has been shown to play a role in the regulation of many cellular processes, including cell growth, apoptosis, and inflammation. It is involved in the regulation of cell cycle progression, and has been shown to promote the G1 phase and the S-phase of the cell cycle. SOX13 is also involved in the regulation of apoptosis, which is the process by which cells die naturally. It has been shown to induce apoptosis in response to various stimuli, including chemotherapy drugs and UV radiation.

SOX13 is also involved in the regulation of inflammation. It has been shown to play a role in the regulation of immune cell function and has been implicated in the development of autoimmune diseases. It is also involved in the regulation of inflammation-related signaling pathways, including the T-cell receptor signaling pathway.

In addition to its role in cellular processes, SOX13 has also been shown to be a potential drug target. Several studies have shown that SOX13 can be targeted by small molecules and have identified potential inhibitors. These inhibitors have been shown to have a range of biological effects, including the inhibition of cell proliferation and the regulation of cellular processes.

SOX13 has also been shown to be a potential biomarker for several diseases. Its involvement in the regulation of cellular processes makes it a promising candidate for the regulation of various diseases. For example, SOX13 has been shown to be involved in the regulation of cancer cell growth and has been implicated in the development of cancer. It has also been shown to be involved in the regulation of autoimmune diseases, including rheumatoid arthritis and lupus.

In conclusion, SOX13 is a non-coding RNA molecule that plays a crucial role in various cellular processes. Its regulation of gene expression and involvement in cellular processes make it a promising candidate for drug targeting. Its potential as a biomarker for the regulation of cancer and autoimmune diseases make it an attractive target for further research. Further studies are needed to fully understand the role of SOX13 in cellular processes and its potential as a drug target and biomarker.

Protein Name: SRY-box Transcription Factor 13

Functions: Transcription factor that binds to DNA at the consensus sequence 5'-AACAAT-3' (PubMed:10871192). Binds to the proximal promoter region of the myelin protein MPZ gene, and may thereby be involved in the differentiation of oligodendroglia in the developing spinal tube (By similarity). Binds to the gene promoter of MBP and acts as a transcriptional repressor (By similarity). Binds to and modifies the activity of TCF7/TCF1, thereby inhibiting transcription and modulates normal gamma-delta T-cell development and differentiation of IL17A expressing gamma-delta T-cells (By similarity). Regulates expression of BLK in the differentiation of IL17A expressing gamma-delta T-cells (By similarity). Promotes brown adipocyte differentiation (By similarity). Inhibitor of WNT signaling (PubMed:20028982)

The "SOX13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SOX13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets